VENTURE LIFE GROUP PLC

Business and Financial Review • Nov 24, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4085X

Venture Life Group PLC

24 November 2017

24 November 2017

VENTURE LIFE GROUP PLC

("Venture Life" or "the Company")

New long term exclusive partner secured in Austrian market

Patent grant for UltraDEX Sensitive

Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces it has secured a new long term exclusive distribution deal in Austria with a new partner for its Procto-eze range. 

Germania Pharmazeutika GesmbH ("Germania") is a privately owned pharmaceutical company focused on products specifically for women's health, diabetes and gastro related issues. Germania will launch all products in the Procto-eze range in 2018. The range comprises of three products: cleanser, cream and wipes. These provide a comprehensive treatment regimen for haemorrhoids and anal irritation for men and women.

Separately, the Company announces that it has received a patent grant for its UltraDEX Sensitive range in Indonesia.  This further strengthens its patent base for UltraDEX Sensitive, as the Company continues its search for international partners. UltraDEX Sensitive will launch next in the Nordic regions in Q1 2018 and final launch plans are in the process of being completed.

Jerry Randall, CEO of Venture Life Group commented: "I am delighted with the appointment of another exclusive long-term partner for the Procto-eze range in an important EU market. This innovative range of products is beginning to get traction in a number of international markets. We continue to see strong levels of interest in our branded portfolio and expect a continued flow of new partner announcements in the future.  In addition, the patent grant in Indonesia adds to the patent estate surrounding the UltraDEX Sensitive range that we currently have already in the EU, USA and many other markets, building on this valuable asset."

Venture Life Group PLC		+44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited (Nominated Adviser and Joint Broker)			+44 (0) 20 3861 6625
Matthew Johnson / Edward Hutton (Corporate Finance)
Bob Pountney / John Howes (Corporate Broking)
Turner Pope Investments (TPI) Ltd (Joint Broker)		+44 (0) 20 3621 4120
James Pope / Ben Turner
Walbrook PR	venturelife@walbrookpr.com or  + 44 (0) 20 7933 8780
Anna Dunphy / Paul McManus	+44 (0) 7876 741 001 / +44 (0) 7980 541 893

About Venture Life (www.venture-life.com) 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population.  The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRBRBDBLSDBGRX